Profile data is unavailable for this security.
About the company
Mabwell Shanghai Bioscience Co Ltd is a China-based company mainly engaged in the research and development, production and sales of therapeutic biological products. The Company's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The Company is also engaged in the organization, management and development of clinical trials of research species. The Company's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The Company conducts business in domestic and foreign markets.
- Revenue in CNY (TTM)191.35m
- Net income in CNY-1.02bn
- Incorporated2017
- Employees1.49k
- LocationMabwell Shanghai Bioscience Co Ltd4th Floor, Building 3No 576 (Chuangxiang Garden)Libing Rd, Pudong New AreaSHANGHAI 201210ChinaCHN
- Phone+86 2 158332260
- Fax+86 2 158585793
- Websitehttps://www.mabwell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 11.87bn | 2.55k | 23.13 | 1.51 | -- | 4.35 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.18bn | 208.25m | 12.06bn | 1.55k | 57.91 | 5.36 | -- | 10.21 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.26bn | 453.31m | 12.25bn | 2.88k | 27.03 | 3.13 | -- | 3.76 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Mabwell Shanghai Bioscience Co Ltd | 191.35m | -1.02bn | 12.97bn | 1.49k | -- | 5.39 | -- | 67.77 | -2.55 | -2.55 | 0.4789 | 6.02 | 0.0412 | 0.0472 | 16.79 | 128,337.60 | -22.02 | -37.61 | -26.37 | -45.95 | 96.84 | 81.54 | -534.78 | -2,112.26 | 1.96 | -- | 0.442 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.43bn | 523.43m | 13.42bn | 8.41k | 25.84 | 1.88 | -- | 2.09 | 0.202 | 0.202 | 2.49 | 2.78 | 0.5568 | 2.39 | 4.60 | 764,058.90 | 5.02 | 6.77 | 7.25 | 10.50 | 54.36 | 63.24 | 9.02 | 11.10 | 1.53 | 40.71 | 0.1459 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.25bn | 989.32m | 13.69bn | 4.88k | 13.80 | 1.57 | -- | 2.61 | 1.10 | 1.10 | 5.84 | 9.69 | 0.4523 | 1.87 | 4.36 | 1,076,055.00 | 8.52 | 10.10 | 11.07 | 13.69 | 35.80 | 34.64 | 18.83 | 16.26 | 2.07 | -- | 0.1816 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.07bn | 352.22m | 13.92bn | 965.00 | 39.52 | 2.79 | -- | 12.97 | 0.571 | 0.571 | 1.74 | 8.09 | 0.2078 | 1.14 | 9.25 | 1,112,527.00 | 6.61 | 1.32 | 6.93 | 1.41 | 77.85 | 80.74 | 31.81 | 6.55 | 6.66 | -- | 0.01 | 8.25 | 22.84 | -2.35 | 497.63 | -4.44 | 21.22 | -- |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 386.57m | -260.85m | 14.00bn | 867.00 | -- | 8.78 | -- | 36.22 | -1.00 | -1.00 | 1.49 | 6.02 | 0.1621 | 0.2594 | 3.75 | 445,874.00 | -11.74 | -27.13 | -20.82 | -39.20 | 92.29 | 92.75 | -72.40 | -220.71 | 2.15 | -- | 0.3842 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.43bn | 614.24m | 14.06bn | 2.53k | 22.74 | 4.76 | -- | 4.10 | 1.09 | 1.09 | 6.09 | 5.21 | 0.7246 | 2.04 | 13.84 | 1,356,471.00 | 12.97 | 10.68 | 21.27 | 16.56 | 71.74 | 74.42 | 17.90 | 14.92 | 1.26 | -- | 0.0122 | 72.80 | 10.31 | 10.03 | 22.09 | 18.49 | -16.47 | 39.77 |
Data as of May 24 2024. Currency figures normalised to Mabwell Shanghai Bioscience Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
27.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 15.61m | 7.74% |
| Haitong Innovation Securities Investment Co Ltd.as of 18 Jan 2024 | 7.82m | 3.88% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 4.44m | 2.20% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 4.36m | 2.16% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 4.35m | 2.16% |
| Penghua Fund Management Co., Ltd.as of 30 Sep 2023 | 4.12m | 2.04% |
| Caitong Fund Management Co., Ltd.as of 30 Jun 2023 | 4.10m | 2.04% |
| Fullgoal Fund Management Co., Ltd.as of 30 Sep 2023 | 3.84m | 1.91% |
| Golden Eagle Asset Management Co., Ltd.as of 31 Dec 2023 | 3.44m | 1.71% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 2.88m | 1.43% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
